Fig. 2: Characteristics of apheresis products after mobilization with MGTA-145 and plerixafor compared with standard of care mobilization (G-CSF and/or on demand plerixafor). | Blood Cancer Journal

Fig. 2: Characteristics of apheresis products after mobilization with MGTA-145 and plerixafor compared with standard of care mobilization (G-CSF and/or on demand plerixafor).

From: Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma

Fig. 2

A HSCs (CD34 + CD90+ and CD34 + CD90 + CD45RA-) shown as % of CD34+ cells assessed by FACS. B T, B and NK cells shown as % of the lymphocytes assessed by FACS. C Frequency of total, memory and naïve CD4 + T cells as assessed by FACS. D Frequency of total, memory and naive CD8 + T cells as assessed by flow cytometry. Each figure shows individual datapoints as circles or squares and the bar represents the median.

Back to article page